Clinical trials: Type2Diabetes
- Condition Type2Diabetes
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Overweight and Obesity, Type2diabetes
Assessment of Safety, Tolerability and Drug Levels of Exenatide Implant
The purpose of this study is to evaluate the safety, tolerability and drug levels of an exenatide implant administered subcutaneously.
- Trial name
- LIBERATE-1 (NCT05670379)
- Testing
- Exenatide Implant, Bydureon BCise (exenatide extended release), Semaglutide, 1.0 mg/mL
- Where
- Australia
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Vivani Medical, Inc
Type2diabetes
Bioequivalence Study to Compare Empagliflozin/ Metformin HCl 12.5mg/1000mg Film-coated Tablets
Randomized, two-way, two-period, single oral dose, open-label, crossover, bioequivalence study to compare Empagliflozin/ Metformin HCl 12.5mg/1000mg film-coated tablets (12.5mg Empagliflozin / 1000mg Metformin HCl) versus…
- Trial name
- NCT06450262
- Testing
- Emapgliflozin/Metformin 12.5mg/1000mg Film-coated tablets, Synjardy® 12.5mg/1000mg film-coated tablets
- Where
- Jordan
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Humanis Saglık Anonim Sirketi
Type2diabetes
The Attractive 2 Trial - Pharmacokinetics of ATR-258 Oral Capsule vs. Oral Solution Formulations in Healthy Volunteers
This is a single-centre, open-label, randomised, 2-period cross-over, Phase 1 comparative trial to assess the ATR-258 pharmacokinetic (PK) parameters of an oral capsule formulation in comparison with an oral solution formulation…
- Trial name
- Attractive 2 (NCT06432673)
- Testing
- ATR-258 Oral solution, ATR-258 Oral capsule
- Where
- Sweden
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Atrogi AB
Type2Diabetes
A Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-393(2) in Healthy Volunteers Under Fed Conditions
A Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-393(2) in Healthy Volunteers Under Fed Conditions
- Trial name
- NCT05347576
- Testing
- CKD-393(2), CKD-501, D759, D150, D029
- Where
- South Korea
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Type 2 Diabetes Mellitus in Obese, Obesity
A Study to Assess 11 Beta-hydroxysteroid Dehydrogenase Type 1 Inhibition in Adipose Tissue by SPI-62
This will be an exploratory, open-label study of 11β-hydroxysteroid dehydrogenase type 1 (HSD-1) inhibition by SPI-62 in obese subjects with type 2 diabetes mellitus (T2DM)
- Conditions
- Type 2 Diabetes Mellitus in Obese, Obesity, Type2Diabetes
- Trial name
- NCT05409027
- Testing
- SPI-62, Cortisone-d8
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Sparrow Pharmaceuticals